Journal of Medicinal Chemistry · 2020 · 76 citations · 18 references
PharmacyMedicinal ChemistryPharmacologyCancer PharmacologyDrug DesignDrug DiscoveryMtor Inhibitor TherapyOncology PharmacologyTargeted Cancer TherapyTargeted TherapyToxicity ManagementBiological Evaluation ReportKinase Selectivity ProfilingMtor InhibitionOral Drug BioavailabilityPathway-based Drug TargetingPi3 Kinase-akt SignalingPi3k InhibitorsPi3k-akt-mtor Signaling
PI3K-Akt-mTOR signaling pathway has been validated as an effective targeting pathway for cancer therapy. However, no PI3K/mTOR dual inhibitor has been approved by the FDA yet. Therefore, it is still essential to discover a candidate with good efficacy and low toxicity. In our design, a series of imidazo[1,2-a]pyridine derivatives had been synthesized and subjected to activity assessment in vitro and in vivo. 15a was proved to be a potent PI3K/mTOR dual inhibitor with excellent kinase selectivity, modest plasma clearance, and acceptable oral bioavailability. Besides, 15a displayed significant inhibition of tumor growth in HCT116 and HT-29 xenografts without obvious effect on body weight.
18
Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex
Dos D. Sarbassov, David A. Guertin, Siraj M. Ali et al. · Science · 2005 · 6.2K citations
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
Kathryn O’Reilly, F. Rojo, Qing‐Bai She et al. · Cancer Research · 2006 · 2.6K citations · Full text
Medicine, Oncology, Pharmacology +16
High-throughput oncogene mutation profiling in human cancer
Roman K. Thomas, Alissa C. Baker, Ralph DeBiasi et al. · Nature Genetics · 2007 · 996 citations
A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations
Yiqun Zhang, Patrick Kwok‐Shing Ng, Melanie H. Kucherlapati et al. · Cancer Cell · 2017 · 656 citations